Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Clinical results and complications of iris fixated phakic intraocular lens to correct high myopia

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Phakic IOLs III

Session Date/Time: Tuesday 13/09/2016 | 09:30-11:00

Paper Time: 09:40

Venue: Poster Village: Pod 4

First Author: : S.Suharyono INDONESIA

Co Author(s): :    B. Dibyasakti   A. Pradipta   W. Doni   A. Supartoto   S. Suhardjo  

Abstract Details

Purpose:

To evaluate the safety and efficiency of phakic IOL for the correction of high myopia

Setting:

Dr. Yap Eye Hospital, Yogyakarta, Indonesia

Methods:

This was conducted as a nonrandomized prospective study of high myop patients 37 eyes who underwent iris fixated P-IOL implantation (Artisan-Artiflex ®) by single operator. Patients age, gender, best corrected visual acuity, intraocular pressure, and endothelial cell count at presentation and at follow-up visits were examined. The follow up times was three months

Results:

The refractive error (spherical equivalent) of the patients ranged between S -7.0 to S -22.25 D. The final mean LogMAR BCVA with PIOL 0.28±0.201, and BCVA spectales 0.40±0.25. Degree of refractive error was positively correlated with visual improvement with PIOL (p=0.002). Mean preoperative central endothelial cell density was 2956±306 cells/mm2, whom was significantly decreased to 2838±265 cells/mm2 (p=0.001) post operative. Intraocular mean wasn’t increased significantly preoperative compared to post operative

Conclusions:

Iris fixated phakic IOL provides good visual and refractive outcomes in patients with high myopia and/or myopic astigmatism. Mild endothelial cell count loss and increase of intraocular pressure make this iris fixated phakic intraocular lens is safe. Further data are needed to asses the impact in endothelial cell count and intra ocular pressure

Financial Disclosure:

NONE

Back to previous